Children younger than 16 years of age at diagnosis with WNT-activated medulloblastomas have consistently achieved favourable outcomes (5-year event-free survival >95%),3, 4 whereas other disease features, including MYC or MYCN amplification, large-cell/anaplastic histology, metastatic disease, or subtotal resection, define high-risk disease (5-year event-free survival <60%).5 The gene discussed is MYCN; the disease is metastatic neoplasm.